xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

512

International consensus statement on rhinosinusitis

with reduced nasal polyp score.

between 3 mg/kg, 1 mg/kg, placebo.

SNOT-20 SNOT-20 better in omalizumab compared to controls.

Mepolizumab group with reduced nasal polyp score.

Sinus imaging No difference between groups.

SNOT-22 SNOT-22 better in omalizumab compared to controls.

No clear differences

Nasal polyp score Omalizumab group

Study Year LOE(1-5) Study Design Study Groups Clinical Endpoint Conclusions Change in nasal polyp score

Change in nasal polyp score

mg/kg, placebo single dose

Omalizumab standard dosing x 16 weeks, placebo

Mostafa 1643h,i 2019 4 Randomized, single-blind Omalizumab 150 once mg or no omalizumab

Mepolizumab 750 IV x 2 doses, 28 days apart; placebo

Omalizumab standard dosing x 6 months, placebo

Bidder 1642 2018 4 Case/control Omalizumab for 16 weeks and no omalizumab

Reslizumab 3 mg/kg, 1

Gevaert 59d 2006 3 Randomized, double blind, placebo

controlled (intranasal

steroids not allowed)

Gevaert 58g 2013 3 Randomized, double blind, placebo

controlled (intranasal steroids unclear)

Gevaert 1644c 2011 3 Randomized, double blind, placebo

controlled (intranasal

steroids not allowed)

Pinto 1174e,f 2010 3 Randomized, double blind, placebo

controlled (intranasal steroids unclear)

TABLE X-26 (Continued)

a LIBERTY NP SINUS-52. b LIBERTY NP SINUS-24. c Rated down for indirectness given that dosing (750 mg IV) used in study is currently not available for use clinically. d Rated down for imprecision (only 8 patients per group) and for inconsistency (3 mg/kg vs 1 mg/kg dosing). e 7/7 in omalizumab CRSwNP; 5/7 in placebo CRSwNP? f Rated down for imprecision. g NP and asthma required to enroll. h CRSwNP and AFRS diagnosis. i Rated down for lack of blinding, imprecision, and outcome selection.